Lamotrigine prevents MK801-induced alterations in early growth response factor-1 mRNA levels and immunoreactivity in the rat brain

Sang Ha Park, Young Ho Seo, Bo Hyun Moon, Song hyen Choi, Seungwoo Kang, Kuem Ju Lee, Sang-Hyun Choi, Min-Soo Lee, Boe Gwun Chun, Kyung-Ho Shin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

MK801 (dizocilpine) induces selective neurotoxic effects in the retrosplenial cortex, ranging from neuronal vacuolization to irreversible neurodegeneration depending on the dose administered. Although lamotrigine prevents MK801-induced neuronal vacuolization in the retrosplenial cortex 4 h after injection, it is not clear whether lamotrigine attenuates the subsequent neurodegeneration that occurs 3-4 days later. Because early growth response factor-1 (egr-1) plays a key role in neurodegeneration and its expression is induced in the retrosplenial cortex following MK801 treatment, it is possible that lamotrigine may attenuate MK801-induced neurodegeneration via inhibition of egr-1 expression in the retrosplenial cortex. To address this issue, we treated rats with lamotrigine (10 or 20 mg/kg) followed by MK801 (2 mg/kg) and measured changes in the levels of egr-1 mRNA and immunoreactivity in the retrosplenial cortex and other brain regions 3 h later. We also evaluated the effects of these treatments on neurodegeneration 4 days following treatment using Fluoro-Jade B staining. MK801 treatment increased egr-1 mRNA and immunoreactivity in the restrosplenial, cingulate, entorhinal and piriform cortices, but decreased levels in hippocampal subfields. These MK801-induced changes in egr-1 expression were significantly inhibited by lamotrigine pretreatment. In addition, MK801-induced neurodegeneration in the retrosplenial cortex was partially blocked by lamotrigine pretreatment in a dose dependent manner. These results demonstrate that lamotrigine pretreatment prevents the MK801-induced upregulation of egr-1 expression in a region-selective manner, and suggest that this effect may contribute, in part, to the attenuation of MK801-induced neurodegeneration in the retrosplenial cortex.

Original languageEnglish
Pages (from-to)58-65
Number of pages8
JournalEuropean Journal of Pharmacology
Volume589
Issue number1-3
DOIs
Publication statusPublished - 2008 Jul 28

Fingerprint

Intercellular Signaling Peptides and Proteins
Messenger RNA
Brain
Entorhinal Cortex
Dizocilpine Maleate
Gyrus Cinguli
Therapeutics
lamotrigine
Up-Regulation
Staining and Labeling
Injections

Keywords

  • Early growth response factor-1
  • Lamotrigine
  • MK801
  • Retrosplenial cortex

ASJC Scopus subject areas

  • Pharmacology

Cite this

Lamotrigine prevents MK801-induced alterations in early growth response factor-1 mRNA levels and immunoreactivity in the rat brain. / Park, Sang Ha; Seo, Young Ho; Moon, Bo Hyun; Choi, Song hyen; Kang, Seungwoo; Lee, Kuem Ju; Choi, Sang-Hyun; Lee, Min-Soo; Chun, Boe Gwun; Shin, Kyung-Ho.

In: European Journal of Pharmacology, Vol. 589, No. 1-3, 28.07.2008, p. 58-65.

Research output: Contribution to journalArticle

Park, Sang Ha ; Seo, Young Ho ; Moon, Bo Hyun ; Choi, Song hyen ; Kang, Seungwoo ; Lee, Kuem Ju ; Choi, Sang-Hyun ; Lee, Min-Soo ; Chun, Boe Gwun ; Shin, Kyung-Ho. / Lamotrigine prevents MK801-induced alterations in early growth response factor-1 mRNA levels and immunoreactivity in the rat brain. In: European Journal of Pharmacology. 2008 ; Vol. 589, No. 1-3. pp. 58-65.
@article{c530573225ec4057b8b3278204067c4e,
title = "Lamotrigine prevents MK801-induced alterations in early growth response factor-1 mRNA levels and immunoreactivity in the rat brain",
abstract = "MK801 (dizocilpine) induces selective neurotoxic effects in the retrosplenial cortex, ranging from neuronal vacuolization to irreversible neurodegeneration depending on the dose administered. Although lamotrigine prevents MK801-induced neuronal vacuolization in the retrosplenial cortex 4 h after injection, it is not clear whether lamotrigine attenuates the subsequent neurodegeneration that occurs 3-4 days later. Because early growth response factor-1 (egr-1) plays a key role in neurodegeneration and its expression is induced in the retrosplenial cortex following MK801 treatment, it is possible that lamotrigine may attenuate MK801-induced neurodegeneration via inhibition of egr-1 expression in the retrosplenial cortex. To address this issue, we treated rats with lamotrigine (10 or 20 mg/kg) followed by MK801 (2 mg/kg) and measured changes in the levels of egr-1 mRNA and immunoreactivity in the retrosplenial cortex and other brain regions 3 h later. We also evaluated the effects of these treatments on neurodegeneration 4 days following treatment using Fluoro-Jade B staining. MK801 treatment increased egr-1 mRNA and immunoreactivity in the restrosplenial, cingulate, entorhinal and piriform cortices, but decreased levels in hippocampal subfields. These MK801-induced changes in egr-1 expression were significantly inhibited by lamotrigine pretreatment. In addition, MK801-induced neurodegeneration in the retrosplenial cortex was partially blocked by lamotrigine pretreatment in a dose dependent manner. These results demonstrate that lamotrigine pretreatment prevents the MK801-induced upregulation of egr-1 expression in a region-selective manner, and suggest that this effect may contribute, in part, to the attenuation of MK801-induced neurodegeneration in the retrosplenial cortex.",
keywords = "Early growth response factor-1, Lamotrigine, MK801, Retrosplenial cortex",
author = "Park, {Sang Ha} and Seo, {Young Ho} and Moon, {Bo Hyun} and Choi, {Song hyen} and Seungwoo Kang and Lee, {Kuem Ju} and Sang-Hyun Choi and Min-Soo Lee and Chun, {Boe Gwun} and Kyung-Ho Shin",
year = "2008",
month = "7",
day = "28",
doi = "10.1016/j.ejphar.2008.04.059",
language = "English",
volume = "589",
pages = "58--65",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Lamotrigine prevents MK801-induced alterations in early growth response factor-1 mRNA levels and immunoreactivity in the rat brain

AU - Park, Sang Ha

AU - Seo, Young Ho

AU - Moon, Bo Hyun

AU - Choi, Song hyen

AU - Kang, Seungwoo

AU - Lee, Kuem Ju

AU - Choi, Sang-Hyun

AU - Lee, Min-Soo

AU - Chun, Boe Gwun

AU - Shin, Kyung-Ho

PY - 2008/7/28

Y1 - 2008/7/28

N2 - MK801 (dizocilpine) induces selective neurotoxic effects in the retrosplenial cortex, ranging from neuronal vacuolization to irreversible neurodegeneration depending on the dose administered. Although lamotrigine prevents MK801-induced neuronal vacuolization in the retrosplenial cortex 4 h after injection, it is not clear whether lamotrigine attenuates the subsequent neurodegeneration that occurs 3-4 days later. Because early growth response factor-1 (egr-1) plays a key role in neurodegeneration and its expression is induced in the retrosplenial cortex following MK801 treatment, it is possible that lamotrigine may attenuate MK801-induced neurodegeneration via inhibition of egr-1 expression in the retrosplenial cortex. To address this issue, we treated rats with lamotrigine (10 or 20 mg/kg) followed by MK801 (2 mg/kg) and measured changes in the levels of egr-1 mRNA and immunoreactivity in the retrosplenial cortex and other brain regions 3 h later. We also evaluated the effects of these treatments on neurodegeneration 4 days following treatment using Fluoro-Jade B staining. MK801 treatment increased egr-1 mRNA and immunoreactivity in the restrosplenial, cingulate, entorhinal and piriform cortices, but decreased levels in hippocampal subfields. These MK801-induced changes in egr-1 expression were significantly inhibited by lamotrigine pretreatment. In addition, MK801-induced neurodegeneration in the retrosplenial cortex was partially blocked by lamotrigine pretreatment in a dose dependent manner. These results demonstrate that lamotrigine pretreatment prevents the MK801-induced upregulation of egr-1 expression in a region-selective manner, and suggest that this effect may contribute, in part, to the attenuation of MK801-induced neurodegeneration in the retrosplenial cortex.

AB - MK801 (dizocilpine) induces selective neurotoxic effects in the retrosplenial cortex, ranging from neuronal vacuolization to irreversible neurodegeneration depending on the dose administered. Although lamotrigine prevents MK801-induced neuronal vacuolization in the retrosplenial cortex 4 h after injection, it is not clear whether lamotrigine attenuates the subsequent neurodegeneration that occurs 3-4 days later. Because early growth response factor-1 (egr-1) plays a key role in neurodegeneration and its expression is induced in the retrosplenial cortex following MK801 treatment, it is possible that lamotrigine may attenuate MK801-induced neurodegeneration via inhibition of egr-1 expression in the retrosplenial cortex. To address this issue, we treated rats with lamotrigine (10 or 20 mg/kg) followed by MK801 (2 mg/kg) and measured changes in the levels of egr-1 mRNA and immunoreactivity in the retrosplenial cortex and other brain regions 3 h later. We also evaluated the effects of these treatments on neurodegeneration 4 days following treatment using Fluoro-Jade B staining. MK801 treatment increased egr-1 mRNA and immunoreactivity in the restrosplenial, cingulate, entorhinal and piriform cortices, but decreased levels in hippocampal subfields. These MK801-induced changes in egr-1 expression were significantly inhibited by lamotrigine pretreatment. In addition, MK801-induced neurodegeneration in the retrosplenial cortex was partially blocked by lamotrigine pretreatment in a dose dependent manner. These results demonstrate that lamotrigine pretreatment prevents the MK801-induced upregulation of egr-1 expression in a region-selective manner, and suggest that this effect may contribute, in part, to the attenuation of MK801-induced neurodegeneration in the retrosplenial cortex.

KW - Early growth response factor-1

KW - Lamotrigine

KW - MK801

KW - Retrosplenial cortex

UR - http://www.scopus.com/inward/record.url?scp=47749151023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749151023&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.04.059

DO - 10.1016/j.ejphar.2008.04.059

M3 - Article

C2 - 18550051

AN - SCOPUS:47749151023

VL - 589

SP - 58

EP - 65

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -